Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma

Journal of Cancer

Volumn 5, Issue 3, 2014, Pages 221-230

  Ozaki, Kazuaki ^a   Toshikuni, Nobuyuki ^a   George, Joseph ^a   Minato, Takahiro ^a   Matsue, Yasuhiro ^a   Arisawa, Tomiyasu ^a   Tsutsumi, Mikihiro ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Endocan; Hepatocellular carcinoma; Prognostic survival

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; ENDOCAN; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; VERY ELDERLY;

EID: 84896931325     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.7691     Document Type: Article

References (42)

1. Patel M, Shariff M I, Ladep N G, et al. Hepatocellular carcinoma: diagnostics and screening. J Eval Clin Pract. 2012; 18: 335-42.
2. Padhya K T, Marrero J A, Singal A G. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013; 29: 285-92.
3. Schoenleber S J, Kurtz D M, Talwalkar J A, Roberts L R, Gores G J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009; 100: 1385-92.
4. Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2012; 12: 56.
5. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996; 271: 20458-64.
6. Bechard D, Meignin V, Scherpereel A, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res. 2000; 37: 417-25.
7. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006; 1765: 25-37.
8. Abid M R, Yi X, Yano K, Shih S C, Aird W C. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res. 2006; 72: 136-45.
9. Rennel E, Mellberg S, Dimberg A, et al. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res. 2007; 313: 1285-94.
10. Scherpereel A, Gentina T, Grigoriu B, et al. Overexpression of endocan induces tumor formation. Cancer Res. 2003; 63: 6084-9.
11. Almog N, Ma L, Raychowdhury R, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 2009; 69: 836-44.
12. Maurage C A, Adam E, Mineo J F, et al. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol. 2009; 68: 633-41.
13. Cornelius A, Cortet-Rudelli C, Assaker R, et al. Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol. 2012; 22: 757-64.
14. Grigoriu B D, Depontieu F, Scherpereel A, et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res. 2006; 12: 4575-82.
15. Liu N, Zhang L H, Du H, et al. Overexpression of endothelial cell specific molecule-1 (ESM-1) in gastric cancer. Ann Surg Oncol. 2010; 17: 2628-39.
16. Ji N Y, Kim Y H, Jang Y J, et al. Identification of endothelial cell-specific molecule-1 as a potential serum marker for colorectal cancer. Cancer Sci. 2010; 101: 2248-53.
17. Kim J H, Park M Y, Kim C N, et al. Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1alpha in human colon carcinoma: impact of ESM-1 on prognosis and its correlation with clinicopathological features. Oncol Rep. 2012; 28: 1701-8.
18. Leroy X, Aubert S, Zini L, et al. Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology. 2010; 56: 180-7.
19. Roudnicky F, Poyet C, Wild P, et al. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res. 2013; 73: 1097-106.
20. El Behery M M, Seksaka M A, Ibrahiem M A, Saleh H S, El Alfy Y. Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer. Arch Gynecol Obstet. 2013.
21. Huang G W, Tao Y M, Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci. 2009; 54: 389-94.
22. Chen L Y, Liu X, Wang S L, Qin C Y. Over-expression of the Endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion. J Int Med Res. 2010; 38: 498-510.
23. Kang Y H, Ji N Y, Lee C I, et al. ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino Acids. 2011; 40: 1003-13.
24. Ziol M, Sutton A, Calderaro J, et al. ESM-1 Expression in Stromal Cells is Predictive for Recurrence after Radiofrequency Ablation in Early Hepatocellular Carcinoma. J Hepatol. 2013.
25. Nault J C, Guyot E, Laguillier C, et al. Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis. Cancer Epidemiol Biomarkers Prev. 2013; 22: 1343-52.
26. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007; 245: 909-22.
27. Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol. 2009; 44 Suppl 19: 119-21.
28. Gunsilius E, Petzer A, Stockhammer G, et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology. 2000; 58: 169-74.
29. Shim J H, Park J W, Kim J H, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 2008; 99: 2037-44.
30. Tyson G L, Duan Z, Kramer J R, et al. Level of alpha-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9: 989-94.
31. Toyoda H, Kumuda T, Nakano S, et al. Significance of tumor vascularity as a predictor of long-term prognosis in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection therapy. J Hepatol. 1997; 26: 1055-62.
32. Maisonpierre P C, Suri C, Jones P F, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997; 277: 55-60.
33. Augustin H G, Koh G Y, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009; 10: 165-77.
34. Scholz A, Rehm V A, Rieke S, et al. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol. 2007; 102: 2471-81.
35. Shimada M, Takenaka K, Fujiwara Y, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer. 1996; 78: 2094-100.
36. Toyoda H, Kumada T, Kiriyama S, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006; 4: 111-7.
37. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012; 107: 569-77; quiz 78.
38. Toyoda H, Kumada T, Tada T, et al. Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. J Hepatol. 2012; 57: 1251-7.
39. Poon R T, Lau C, Pang R, et al. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol. 2007; 14: 1835-45.
40. Tamesa T, Iizuka N, Mori N, et al. High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology. 2009; 56: 1122-6.
41. Zhong C, Wei W, Su X K, et al. Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection. Hepatogastroenterology. 2012; 59: 93-7.
42. Kang Y H, Ji N Y, Han S R, et al. ESM-1 regulates cell growth and metastatic process through activation of NF-kappaB in colorectal cancer. Cell Signal. 2012; 24: 1940-9.